VIMAL DRUGS PVT LTD
| Business category 1 | Slate |
| City ( of main office ) | Hyderābād, IN, India |
| Address | 7-1-304 / 6 / 34 Aditya Nagar, B. K. Guda, S. R. Post. |
| Phones | 91-040-23702846 |
| Fax | 91-040-23707143 |
| About | VIMAL DRUGS PVT. LTD. (VDPL) is incorporated as Private Limited Company in the year may 2009. VDPL is an integrated Active Pharmaceutical Ingredients. (APIs) and intermediates manufacturing company based at Visakhapatnam. The Company is propose to engage in the manufacture of high quality Active Pharmaceuticals Ingredients & Intermediates. VDPL has acquired 2.00 acres of land at Jawaharlal Nehru Pharma City at Parwada,Visakhapatnam, with a view to create total Pharma infrastructure viz., Main Production Block, Civil, consisting of clean rooms, Major equipment and Utilites to support the high class facility. THE POTENTIAL GLOBAL SCENE The Indian Pharma industry stands at $7 bilion, with the domestic market making up $4.5 billion an dexports totaling to $2.5 billion. Over the next decade, the industry could grow five-fold to touch $35 billion. More important, the indian pharma industry has the potential to merge with the global industry at all points of the value chain ranging from raw materials, intermediates and active pharmaceutical ingredients at one end to the generic and outsourced formulations and drug discovery and development at the other end. The industry is also likely to synergise its capabilities in the fields of IT, biology,medicine and pharmaceutical sciences to provide a host of services ranging form bio-informatics, bio-pharmaceuticals, clinical studies and IT-based services. With 80 percent of global retail sales estimated at $466 billion, concentrated in the developed markets of the US, the EU and Japan, there is ample opportunity for the indian pharma industry. PROSPECTS OF THE COMPANY The determinants of success in the pharmaceutical industry are rooted in product discrimintaion(ability to have didicated facilities for product development and manufacture), environmental integrity (ability to maintain environmental clas and aseptic conditions) and regulatory compliance (ability to run product develpment and manufacture as per a set of stringent standard operating procedures). These entail a need to commit investments and develop skills that are practice-specific rather than volume or profit driven. The Indian pharmaceutical industry, accordingly, needs to organise itself into three distinct layers. The apex level would comprise a few global, end product manufactures which are diversified and integrated players with competencies across the specturm of bulk drugs, formulations and drug discovery. The second, senior level would include several global manufactures that are specialists in bulk drugs, formulation or drug discovery. The foundation level would comprise several national manufacturers which provide basic materials, intermediates or services. VDPL stives to occupy a premier position in the third slot by positioning itself as a qulity supplier of bulk drugs and its intermediates of different therapeutic uasge having high demand. The association of the promoters with different value chains of the industry viz. Finance, Marketing procurement, & Administration (by Executive Director Sri. Shaik Alli ) puts VDPL to enter in to the manufacturing of intermediates and bulk drugs. The company is planning to construct the unit as per GMP norms. The product mix of the company has been chosen judiciously to cater to a wide segment of end user industrie, which are expected to grow healthily in near future. The Indian Pharma industry, which is currently driven by generics, is slated to emerge as a source of global drug candidates over the next five to seven years and proprietary products will drive long term growth. Summing up, the Indian pharmaceutical industry is at the cusp of dominating the global industrial space. If the government, industry and individual companies act in concert to usher in reforms that strengthen knowledge and compliance, reshape industry sturcture and enable differentiated corporate strategies, india will be positioned to emerge as the pharma inc |
| Date | 2011 Oct 29, 09:10 |